Harmonised relative effectiveness discussions moving ahead in Europe
This article was originally published in Scrip
Support for a single European relative effectiveness assessment done by the European Medicines Agency (EMA) is gaining momentum with the pharmaceutical industry, said Andrew Witty, president of the European pharmaceutical industry federation EFPIA at its annual meeting in London this week.
You may also be interested in...
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.
The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices.
Luxembourg’s new regulator will work to attract investment and improve public health as well as tackle the growing problem of drug shortages.